Lung Cancer Clinical Trials in Detroit

Showing 321-340 of 645 trials

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Lung Cancer

Hummingbird Diagnostics2,000 participantsStarted Oct 2023

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +5 more locations

WITHDRAWNPhase 1/2< 1 mile

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

NCT04151563

This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy

Carcinoma, Non-small Cell Lung Cancer

Bristol-Myers SquibbStarted Apr 2021

Detroit, Michigan, United States • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina • Buenos Aires, Distrito Federal, Argentina +20 more locations

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung Cancer Trials in Other Cities

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Prospective Clinicogenomic Program

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

The Lung Screening, Tobacco and Health Project

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Detroit